Please Wait...

Protocol Design and Expert Reporting

Study design and Consultative Services

In this highly dynamic and competitive business environment, it is important to have a partner that can help you successfully navigate through the complex drug development process. Whether your team is ready to conduct your company's first TQT study, needs assistance in determining study design options and technology for defining a blood pressure signal for your protocol, or advanced training on medical imaging best practices, Bioclinica can help. We provide a full range of consultancy and reporting services supporting cardiovascular safety throughout the clinical development of your compound.

Our services include:

  • Expert protocol development and study design
  • Statistical analysis plans
  • Expert summary reports for inclusion in the Clinical Study Report
  • Regulatory guidance and support
  • Charter development

Bioclinica is committed to providing you with the highest level of service. The team assigned to your cardiac safety study will provide expert advice on clinical and regulatory strategy, tailored to the framework of your program and specific compound. Engage our team of experts early to assist in developing an effective, comprehensive drug development program and trial protocol.

Cardiac Safety Analysis and Expert Reporting

Bioclinica recognizes the need to provide comprehensive services from study design and conduct to expert reporting of cardiac safety data. We possess strong capabilities in analyzing and presenting ECG/ABPM/CV data in regulatory, expert report format, and we support regulatory meetings and presentations. Our statistical and medical writing team has authored more than 250 expert reports, most of which supported regulatory submissions and full TQT protocol development.

ADDITIONAL RESOURCES

Cardiovascular Solutions

Download BROCHURE

Global Median Beat (GMB)

Download OVERVIEW SHEET

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

RT @MdFacep: FDA approvals: Merck's Keytruda wins FDA approval as combination therapy for kidney cancer. BIG! https://t.co/LgCzL1mvaF @Reu…
Bioclinica (8 hours ago)
RT @FDA_Drug_Info: National Prescription Drug Take Back Day is April 27, 2019 from 10:00 AM to 2:00 PM. Learn how to dispose of unused and…
Bioclinica (8 hours ago)
RT @iofbonehealth: #Osteoporosis Int: Spanish National Hip Fracture Registry (RNFC): analysis of its first annual report and international…
Bioclinica (8 hours ago)
RT @HINJ_ORG: New Jersey's biopharmaceutical industry: CIANJ has assembled a panel of industry leaders @Celgene, @Bayer & @PhRMA to discuss…
Bioclinica (8 hours ago)
RT @PhRMA: Last year, the top 15 largest biopharmaceutical companies spent more than $100 billion on R&D, according to @IQVIA_global. More…
Bioclinica (8 hours ago)
RT @SCDM_DataDriven: Registrations for the SCDM 2019 Annual Conference are now open!! #SCDM2019 Register now for the biggest event in the…
Bioclinica (8 hours ago)

Latest Blogs:

Site Payments Solutions
Nonalcoholic steatohepatitis (NASH) development programs
Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box